Latest Breaking News On - Carsgen therapeutics holdings - Page 3 : comparemela.com

Two Cases of Pancreatic Cancer Treatment with CARsgen's CT041 Published in Journal of Hematology & Oncology

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.

CARsgen Announced 2023 Interim Results

Global Monoclonal Antibodies Market Landscape Assessment 2023: Developments, Trends, Competitors and Products

/PRNewswire/ The "Monoclonal Antibodies - Competitive Landscape, 2023" report has been added to ResearchAndMarkets.com s offering. This report provides.

Monoclonal Antibodies Clinical Trial Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

/PRNewswire/ DelveInsight s Monoclonal Antibodies Competitive Landscape – 2023 report provides comprehensive global coverage of available, marketed, and.

CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.

/PRNewswire/ CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of.